FDA grants Illumina’s TruSight Assay Breakthrough Device designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has granted Breakthrough Device Designation for Illumina’s its pan-cancer assay.

Currently in development, with plans to be marketed as TruSight Oncology Comprehensive, the assay is based on the content of Illumina’s TruSight Oncology 500, designed to detect known and emerging solid tumor biomarkers. Illumina is seeking FDA approval of the assay as a companion diagnostic.

The assay utilizes both DNA and RNA from tumor samples to identify key somatic variants underlying tumor progression. These variants include small DNA variants, fusions, and splice variants, as well as immunotherapy-associated biomarkers such as tumor mutational burden and microsatellite instability, features that are potentially key biomarkers for immunotherapies.

The Breakthrough Device Program, which supersedes the FDA’s Expedited Access Pathway, is designed for certain medical devices and device-led combination products that provide for more effective treatment in diagnosing life-threatening or irreversibly debilitating diseases or conditions.

The Breakthrough Devices Program contains features of the EAP, as well as the Innovation Pathway, both of which were intended to facilitate the development and expedite the review of breakthrough technologies.

With Breakthrough Device Designation, Illumina’s assay will receive priority review, meaning that the review of the submission is prioritized in the queue and will receive additional review resources, as needed.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login